We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Read MoreHide Full Article
Burlington, MA-based Aldeyra Therapeutics (ALDX - Free Report) is a leader in the development of RASP (reactive aldehyde species) modulators for the treatment of immune-mediated diseases. Lately, it has seen success in its studies on its investigational RASP modulator, ADX-629, which has demonstrated potential activity in clinical studies of patients with psoriasis, asthma, COVID, ethanol toxicity, chronic cough and atopic dermatitis.
Aldeyra Therapeutics is conducting a phase II study on ADX-629 in Sjögren-Larsson Syndrome and moderate alcoholic hepatitis. Based on positive biomarker results observed in the adult cohort of the phase II study of ADX-629 in Sjögren-Larsson Syndrome, Aldeyra Therapeutics plans to expand the study to include pediatric patients for which a proposed expansion is expected to be filed with the FDA in the first half of 2024.
At present, there is no FDA-approved therapy for Sjögren-Larsson Syndrome, a rare inborn error of metabolism due to mutations in fatty aldehyde dehydrogenase, which results in the accumulation of fatty alcohols and fatty aldehydes. Initial clinical data from the Sjögren-Larsson Syndrome study on ADX-629 demonstrated broad-based normalization of the majority of abnormal metabolomic signatures along with a reduction in the accumulation of fatty alcohols in patients treated with ADX-629.
Top-line results from the moderate alcoholic hepatitis study are expected in the second half of 2024.
Clinical studies on two other investigational RASP modulators, ADX-246 (atopic dermatitis) and ADX-248 (immune-mediated diseases of the retina), are expected to begin in the first half of 2024.
Aldeyra Therapeutics stock has risen 12% so far this year against a increase of 1.1% for the industry.
Image Source: Zacks Investment Research
The consensus estimate for 2024 loss has narrowed from $1.08 per share to 45 cents per share over the past 60 days. The company has a Zacks Rank #2 (Buy).
Estimates for Indivior’s 2024 earnings per share have increased from $1.83 to $1.95 over the past 30 days. Estimates for 2025 have jumped from $2.37 to $2.60 over the same timeframe. INDV’s stock has surged 42.1% year to date.
Indivior beat estimates in the last three quarters, delivering an earnings surprise of 48.06% on average. Indivior commenced trading on Nasdaq in June 2023.
In the past 30 days, estimates for Collegium Pharmaceutical’s 2024 earnings per share have improved from $6.11 to $6.29. During the same period, estimates for 2025 have improved from $6.63 per share to $6.87 per share. Year to date, shares of COLL have rallied 18.0%.
COLL’s earnings beat estimates in three of the trailing four quarters while delivering in-line results in one, with the average surprise being 7.54%.
In the past 30 days, estimates for Lyra Therapeutics’ 2024 loss per share have narrowed from $1.08 to $1.07 per share. Year to date, shares of LYRA have rallied 6.9%.
LYRA’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 8.81%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Burlington, MA-based Aldeyra Therapeutics (ALDX - Free Report) is a leader in the development of RASP (reactive aldehyde species) modulators for the treatment of immune-mediated diseases. Lately, it has seen success in its studies on its investigational RASP modulator, ADX-629, which has demonstrated potential activity in clinical studies of patients with psoriasis, asthma, COVID, ethanol toxicity, chronic cough and atopic dermatitis.
Aldeyra Therapeutics is conducting a phase II study on ADX-629 in Sjögren-Larsson Syndrome and moderate alcoholic hepatitis. Based on positive biomarker results observed in the adult cohort of the phase II study of ADX-629 in Sjögren-Larsson Syndrome, Aldeyra Therapeutics plans to expand the study to include pediatric patients for which a proposed expansion is expected to be filed with the FDA in the first half of 2024.
At present, there is no FDA-approved therapy for Sjögren-Larsson Syndrome, a rare inborn error of metabolism due to mutations in fatty aldehyde dehydrogenase, which results in the accumulation of fatty alcohols and fatty aldehydes. Initial clinical data from the Sjögren-Larsson Syndrome study on ADX-629 demonstrated broad-based normalization of the majority of abnormal metabolomic signatures along with a reduction in the accumulation of fatty alcohols in patients treated with ADX-629.
Top-line results from the moderate alcoholic hepatitis study are expected in the second half of 2024.
Clinical studies on two other investigational RASP modulators, ADX-246 (atopic dermatitis) and ADX-248 (immune-mediated diseases of the retina), are expected to begin in the first half of 2024.
Aldeyra Therapeutics stock has risen 12% so far this year against a increase of 1.1% for the industry.
Image Source: Zacks Investment Research
The consensus estimate for 2024 loss has narrowed from $1.08 per share to 45 cents per share over the past 60 days. The company has a Zacks Rank #2 (Buy).
Aldeyra Therapeutics, Inc. Price and Consensus
Aldeyra Therapeutics, Inc. price-consensus-chart | Aldeyra Therapeutics, Inc. Quote
Other Stocks to Consider
Some other top-ranked drug/biotech companies worth considering are Indivior (INDV - Free Report) , Collegium Pharmaceutical (COLL - Free Report) and Lyra Therapeutics (LYRA - Free Report) . While Indivior and Collegium Pharmaceutical sport a Zacks Rank #1 (Strong Buy) each, Lyra Therapeutics has a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Indivior’s 2024 earnings per share have increased from $1.83 to $1.95 over the past 30 days. Estimates for 2025 have jumped from $2.37 to $2.60 over the same timeframe. INDV’s stock has surged 42.1% year to date.
Indivior beat estimates in the last three quarters, delivering an earnings surprise of 48.06% on average. Indivior commenced trading on Nasdaq in June 2023.
In the past 30 days, estimates for Collegium Pharmaceutical’s 2024 earnings per share have improved from $6.11 to $6.29. During the same period, estimates for 2025 have improved from $6.63 per share to $6.87 per share. Year to date, shares of COLL have rallied 18.0%.
COLL’s earnings beat estimates in three of the trailing four quarters while delivering in-line results in one, with the average surprise being 7.54%.
In the past 30 days, estimates for Lyra Therapeutics’ 2024 loss per share have narrowed from $1.08 to $1.07 per share. Year to date, shares of LYRA have rallied 6.9%.
LYRA’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 8.81%.